*****A)Enlist VECTOR BORNE DISEASES(classification basing on type of vector) B) MALARIA a) Epidemiology b)***** malarial indices c) life cycle d) Prevention and control measures e) Add a note on MOSQUIRIX. I want this essay question answer for university spm exam from standard textbook Include flowcharts and diagrams for nice presentation where ever needed ,and how to present in the exam for nice score

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Here is a complete, structured university SPM exam answer - written exactly as you should present it in your exam for maximum marks. All content is sourced from Park's Textbook of Preventive & Social Medicine.

VECTOR-BORNE DISEASES AND MALARIA

(Standard SPM Exam Answer)

Exam Tip: Always start with a brief one-line definition, use headings for each sub-part, draw flow charts / diagrams wherever asked, and end with a 2-line conclusion. The examiner rewards clarity and structured presentation.

A) VECTOR-BORNE DISEASES - Classification Based on Type of Vector

Definition: A vector is defined as an arthropod or any living carrier (e.g., snail) that transports an infectious agent from an infected to a susceptible individual. Transmission may be mechanical or biological.

CLASSIFICATION OF VECTOR-BORNE DISEASES

I. BY TYPE OF VECTOR

A. Invertebrate (Arthropod) Vectors - 7 Orders:

┌─────────────────────────────────────────────────────────────────┐
│              ARTHROPOD VECTORS (7 ORDERS)                       │
├────────────────────┬────────────────────────────────────────────┤
│ Order              │ Vector & Disease                           │
├────────────────────┼────────────────────────────────────────────┤
│ 1. Diptera         │ Flies & Mosquitoes                         │
│                    │ → Malaria, Dengue, Filaria, Kala-azar       │
├────────────────────┼────────────────────────────────────────────┤
│ 2. Siphonaptera    │ Fleas                                      │
│                    │ → Plague, Murine typhus                     │
├────────────────────┼────────────────────────────────────────────┤
│ 3. Orthoptera      │ Cockroaches                                │
│                    │ → Mechanical transmission of gut pathogens  │
├────────────────────┼────────────────────────────────────────────┤
│ 4. Anoplura        │ Sucking Lice                               │
│                    │ → Epidemic typhus, Relapsing fever          │
├────────────────────┼────────────────────────────────────────────┤
│ 5. Hemiptera       │ Bugs (Kissing bugs)                        │
│                    │ → Chagas disease                            │
├────────────────────┼────────────────────────────────────────────┤
│ 6. Acarina         │ Ticks & Mites                              │
│                    │ → Scrub typhus, Rocky Mountain fever        │
├────────────────────┼────────────────────────────────────────────┤
│ 7. Copepoda        │ Cyclops                                    │
│                    │ → Guinea worm (Dracunculiasis)              │
└────────────────────┴────────────────────────────────────────────┘

B. Vertebrate Vectors: Mice, Rodents, Bats

II. BY TRANSMISSION CHAIN

┌──────────────────────────────────────────────────────────────────┐
│              TRANSMISSION CHAIN PATTERNS                         │
├──────────────────────────────────────────────────────────────────┤
│ (a) Man + Non-vertebrate host (2-link chain)                     │
│     • Man → Arthropod → Man       (e.g., Malaria)               │
│     • Man → Snail → Man           (e.g., Schistosomiasis)       │
├──────────────────────────────────────────────────────────────────┤
│ (b) Man + Another vertebrate + Non-vertebrate (3-link chain)     │
│     • Mammal → Arthropod → Man    (e.g., Plague)                │
│     • Bird → Arthropod → Man      (e.g., Encephalitis)          │
├──────────────────────────────────────────────────────────────────┤
│ (c) Man + 2 intermediate hosts (4-link chain)                    │
│     • Man → Cyclops → Fish → Man  (Fish tapeworm)               │
│     • Man → Snail → Fish → Man    (Clonorchis sinensis)         │
│     • Man → Snail → Crab → Man    (Paragonimiasis)              │
└──────────────────────────────────────────────────────────────────┘

III. BY METHOD OF TRANSMISSION

Method	Example
Biting	Malaria (Anopheles), Dengue (Aedes)
Regurgitation	Plague (flea regurgitates bacilli)
Scratching-in of infective faeces	Epidemic typhus (louse faeces)
Contamination with body fluids	Soft tick-borne relapsing fever

IV. BY MECHANISM (Mechanical vs Biological)

              VECTOR TRANSMISSION
                     │
        ┌────────────┴──────────────┐
        ▼                           ▼
  MECHANICAL                   BIOLOGICAL
  (Agent unchanged               (Agent develops/
   in vector)                    multiplies in vector)
        │                           │
  e.g., Housefly                    ├─ Propagative
  carrying cholera                  │  (multiplication only)
  on legs/body                      │  e.g., Plague (flea)
                                    │
                                    ├─ Cyclo-propagative
                                    │  (development + multiplication)
                                    │  e.g., Malaria (mosquito)
                                    │
                                    └─ Cyclodevelopmental
                                       (development only, no mult.)
                                       e.g., Filaria (mosquito)

B) MALARIA

"Malaria is a protozoal disease caused by infection with parasites of the genus Plasmodium and transmitted to man by certain species of infected female Anopheline mosquito." - Park's Textbook of PSM

A typical attack has 3 stages: Cold stage → Hot stage → Sweating stage

a) EPIDEMIOLOGY OF MALARIA

HOST-AGENT-ENVIRONMENT TRIAD

                    ┌─────────────────┐
                    │  AGENT          │
                    │ Plasmodium spp. │
                    │ P. vivax        │
                    │ P. falciparum   │
                    │ P. malariae     │
                    │ P. ovale        │
                    └────────┬────────┘
                             │
           ┌─────────────────┼──────────────────┐
           ▼                                     ▼
┌──────────────────┐                  ┌──────────────────────┐
│   HOST           │                  │  ENVIRONMENT         │
│                  │                  │                      │
│ Human (definitive│                  │ • Temperature:       │
│  host for sexual │                  │   16–33°C optimal    │
│  stage)          │                  │ • Humidity: >60%     │
│                  │                  │ • Rainfall: breeding │
│ Mosquito         │                  │ • Altitude: <2000m   │
│ (Anopheles,      │                  │ • Man-made malaria:  │
│  intermediate    │                  │   dams, irrigation,  │
│  host for        │                  │   construction       │
│  asexual stage)  │                  │                      │
└──────────────────┘                  └──────────────────────┘

CAUSATIVE AGENTS - Species & Periodicity

Species	Fever Periodicity	Form	Severity
P. vivax	Every 48 hrs (Tertian)	Benign tertian	Mild-Moderate
P. falciparum	Every 36–48 hrs	Malignant tertian	SEVERE
P. malariae	Every 72 hrs (Quartan)	Quartan malaria	Mild
P. ovale	Every 48 hrs	Benign tertian	Mild

GLOBAL BURDEN (WHO Data)

~229 million malaria cases in 2019 across 87 endemic countries
Sub-Saharan Africa bears ~90% of the burden
India: Reduced from ~20 million cases (2000) to 5.6 million (2019)
India contributes the largest absolute reduction in South-East Asia Region

DETERMINANTS OF MALARIA IN INDIA

Host Factors:

Age: Children & non-immune adults most susceptible
Immunity: Natural immunity builds up with repeated exposure
Pregnancy: Increased susceptibility, risk of low birth weight
Sickle cell trait: Provides some protection against P. falciparum
G6PD deficiency: At risk for hemolysis with primaquine

Agent Factors (Vectors):

~45 species of anophelines in India; only few are major vectors
Rural areas: An. culicifacies (primary vector)
Urban areas: An. stephensi
Others: An. fluviatilis, An. minimus, An. sundaicus, An. maculatus

Vectorial Capacity Determinants:

┌─────────────────────────────────────────────────────┐
│         FACTORS DETERMINING VECTOR IMPORTANCE       │
│                                                     │
│  a) Density      → Must exceed "critical density"   │
│  b) Life span    → Must survive ≥10-12 days after   │
│                    infective blood meal              │
│  c) Host choice  → Anthropophilic > Zoophilic       │
│  d) Resting habit→ Endophily (indoors) allows IRS   │
│  e) Breeding     → Fresh/slow-moving/stagnant water │
│  f) EIP          → Extrinsic incubation period      │
└─────────────────────────────────────────────────────┘

Environmental Factors:

Temperature: 20–30°C optimal (sporogony ceases <16°C or >33°C)
Humidity: >60% needed for vector survival
Rainfall: Creates breeding sites; heavy rain paradoxically reduces them
Altitude: Anophelines absent above 2000-2500 metres
Man-made malaria: Dams, irrigation, construction projects

b) MALARIAL INDICES

Exam Tip: This is a HIGH-YIELD section. Classify them clearly into Pre-eradication and Eradication era indices.

┌──────────────────────────────────────────────────────────────────┐
│                     MALARIAL INDICES                             │
├──────────────────────────────────────────────────────────────────┤
│  PRE-ERADICATION ERA         │  ERADICATION ERA (Current)        │
│  (Clinical / Spleen-based)   │  (Parasitological / Active surv.) │
├──────────────────────────────┼───────────────────────────────────┤
│  1. Spleen Rate              │  1. API (Annual Parasite          │
│  2. Avg. Enlarged Spleen     │      Incidence)                   │
│  3. Parasite Rate            │  2. ABER (Annual Blood            │
│  4. Parasite Density Index   │      Examination Rate)            │
│  5. Infant Parasite Rate     │  3. AFI (Annual Falciparum        │
│  6. Proportional Case Rate   │      Incidence)                   │
│                              │  4. SPR (Slide Positivity Rate)   │
│                              │  5. SFR (Slide Falciparum Rate)   │
└──────────────────────────────┴───────────────────────────────────┘

PRE-ERADICATION ERA INDICES (Malariometric Indices)

1. Spleen Rate

% of children aged 2-10 years with enlarged spleen
Adults excluded (other causes of splenomegaly confound results)
Most widely used index of malaria endemicity
Endemicity Classification:

  Spleen Rate     Endemicity Level
  ─────────────────────────────────
  < 10%        → Hypoendemic
  10–50%       → Mesoendemic
  51–75%       → Hyperendemic
  > 75%        → Holoendemic

2. Average Enlarged Spleen (AES)

Refinement of spleen rate - denotes average SIZE of enlarged spleen
Graded on Hackett's scale (0-5)
Useful malariometric index

3. Parasite Rate

% of children 2-10 years with malaria parasites in blood films
Correlates with spleen rate

4. Parasite Density Index

Indicates the average degree of parasitaemia in a sample of defined population
Only positive slides included in denominator

5. Infant Parasite Rate

% of infants below 1 year showing malaria parasites in blood films
Most sensitive index of RECENT transmission
If IPR = 0 for 3 consecutive years → absence of transmission confirmed

6. Proportional Case Rate

Number of clinical malaria cases per 100 patients attending hospitals/dispensaries
Crude index (not related to time/space distribution)

ERADICATION ERA INDICES (Parasitological - Currently Used)

1. Annual Parasite Incidence (API)

           Confirmed cases during one year
  API  =  ──────────────────────────────── × 1000
               Population under surveillance

Gold standard - based on active + passive surveillance
API ≥ 2/1000/year = High risk area (eligible for vector control in India)
Most sophisticated measure of malaria incidence

2. Annual Blood Examination Rate (ABER)

          Number of slides examined
  ABER = ─────────────────────────── × 100
                Population

Index of operational efficiency of the program
Target: Examine ≥10% of population annually

3. Annual Falciparum Incidence (AFI)

Similar formula to API but for P. falciparum cases only
Tracks the more dangerous species separately

4. Slide Positivity Rate (SPR)

          Positive slides
  SPR =  ──────────────── × 100
          Slides examined

% of slides found positive (any species)
Indicates trend of malaria transmission

5. Slide Falciparum Rate (SFR)

% of slides positive specifically for P. falciparum
Monitors dangerous falciparum malaria trend

c) LIFE CYCLE OF MALARIA PARASITE (Plasmodium)

The malaria parasite undergoes a complex two-host life cycle - sexual phase in female Anopheles mosquito, asexual phase in humans.

╔══════════════════════════════════════════════════════════════════╗
║              LIFE CYCLE OF PLASMODIUM                           ║
╠═══════════════════════════╦══════════════════════════════════════╣
║  IN HUMAN (Asexual Phase) ║  IN MOSQUITO (Sexual Phase)         ║
╠═══════════════════════════╬══════════════════════════════════════╣
║                           ║                                     ║
║  STEP 1: SPOROZOITES      ║  STEP 7: GAMETOCYTES ingested       ║
║  injected with mosquito   ║  by female Anopheles during         ║
║  saliva during bite       ║  blood meal                         ║
║         ↓                 ║          ↓                          ║
║  STEP 2: LIVER STAGE      ║  STEP 8: GAMETOGENESIS in           ║
║  (Pre-erythrocytic/       ║  mosquito gut                       ║
║   Exoerythrocytic phase)  ║  (Macro + Microgametes)             ║
║  Sporozoites → Liver cell ║          ↓                          ║
║  → Schizogony →           ║  STEP 9: FERTILIZATION              ║
║  Hepatic schizonts →      ║  → OOKINETE (zygote)                ║
║  Merozoites released      ║          ↓                          ║
║  (Incubation: 5-15 days)  ║  STEP 10: OOCYST forms in          ║
║         ↓                 ║  gut wall → Sporozoites develop     ║
║  STEP 3: ERYTHROCYTIC     ║          ↓                          ║
║  PHASE (RBC invasion)     ║  STEP 11: SPOROZOITES               ║
║  Merozoites → RBC →       ║  migrate to SALIVARY GLANDS         ║
║  Trophozoite → Schizont   ║  → ready to infect next human       ║
║         ↓                 ║          ↓                          ║
║  STEP 4: SCHIZOGONY        ║  EXTRINSIC INCUBATION PERIOD       ║
║  RBC ruptures, releases   ║  (EIP) = 10-14 days                 ║
║  Merozoites + toxins      ║  (Minimum: 8-10 days)               ║
║  → FEVER PAROXYSM         ║                                     ║
║         ↓                 ║                                     ║
║  STEP 5: REINVASION        ║                                     ║
║  New RBCs invaded         ║                                     ║
║  (cycle repeats every     ║                                     ║
║   48 or 72 hours)         ║                                     ║
║         ↓                 ║                                     ║
║  STEP 6: GAMETOCYTE       ║                                     ║
║  FORMATION                ║                                     ║
║  Some merozoites →        ║                                     ║
║  Macro & Microgametocytes ║                                     ║
║  (taken up by mosquito)   ║                                     ║
╚═══════════════════════════╩══════════════════════════════════════╝

Key Points for Exam:

Definitive host = Female Anopheles (sexual cycle occurs)
Intermediate host = Human (asexual cycle occurs)
P. vivax & P. ovale: Form hypnozoites (dormant forms) in liver → cause RELAPSES
P. falciparum: Does NOT form hypnozoites; no true relapse but RECRUDESCENCE occurs
EIP (Extrinsic Incubation Period): 10-14 days in mosquito
Intrinsic Incubation Period (IIP): 10-14 days in humans (P. falciparum = 7-14 days; P. vivax = 14 days; P. malariae = 21-40 days)

d) PREVENTION AND CONTROL OF MALARIA

╔══════════════════════════════════════════════════════════════════╗
║         APPROACHES TO MALARIA CONTROL (INDIA)                   ║
╠══════════════════════════════════════════════════════════════════╣
║  (a) SURVEILLANCE & CASE MANAGEMENT                             ║
║  (b) INTEGRATED VECTOR MANAGEMENT                               ║
║  (c) EPIDEMIC PREPAREDNESS & EARLY RESPONSE                     ║
║  (d) SUPPORTIVE INTERVENTIONS                                   ║
╚══════════════════════════════════════════════════════════════════╝

(a) SURVEILLANCE AND CASE MANAGEMENT

CASE DETECTION
  ├── PASSIVE: Patient self-reports to health facility
  └── ACTIVE: Health worker goes to community for fever surveys

        ↓
DIAGNOSIS
  ├── Microscopy (Blood smear - Gold Standard)
  ├── Rapid Diagnostic Tests (RDTs) - detect HRP-2 antigen
  └── Clinical diagnosis (presumptive - NOT recommended now)

        ↓
EARLY AND COMPLETE TREATMENT (AIMS):
  1. Complete cure
  2. Prevention of progression to severe disease
  3. Prevention of deaths
  4. Interruption of transmission
  5. Minimizing drug resistance

Treatment Guidelines (India 2013 - Revised Drug Policy):

No presumptive treatment - all cases must be confirmed first
P. vivax: Chloroquine 25 mg/kg over 3 days + Primaquine 0.25 mg/kg/day for 14 days
P. falciparum (uncomplicated): Artemisinin-based Combination Therapy (ACT)
Severe malaria: IV Artesunate/Quinine + supportive care

(b) INTEGRATED VECTOR MANAGEMENT (IVM)

1. Indoor Residual Spraying (IRS)

Principle: Spray residual insecticide on INDOOR walls/surfaces
           where endophilic mosquitoes rest after blood meal
           → Mosquito life span shortened to <10 days
           → Below EIP → Cannot transmit malaria

Insecticides used:
  • DDT (first used, becoming resistant)
  • Malathion
  • Synthetic pyrethroids (deltamethrin, lambda-cyhalothrin)

2. Insecticide-Treated Bed Nets (ITNs) / Long-Lasting Insecticidal Nets (LLINs)

Physical barrier + insecticidal effect
LLINs effective for 3-5 years without re-treatment
Recommended especially for: pregnant women, children under 5 years

3. Anti-larval Measures (Source Reduction)

Method	Examples
Environmental management	Draining stagnant water, filling pits, clearing vegetation
Biological control	Larvivorous fish (Gambusia, Lebistes), Bacillus thuringiensis
Chemical larvicides	Temephos (abate), pyrethrum oil
Source reduction	Removing collections of water in containers, tyres, pots

(c) PERSONAL PROTECTIVE MEASURES

┌─────────────────────────────────────────────────────────┐
│             PERSONAL PROTECTION                         │
│                                                         │
│  1. Use of insect repellents (DEET-based)               │
│  2. Protective clothing (full-sleeve clothes, socks)    │
│  3. Use of bed nets (preferably ITNs/LLINs)             │
│  4. Window/door screening                               │
│  5. Mosquito coils, vaporizers, repellent mats          │
│  6. Chemoprophylaxis for travellers/high-risk groups    │
│     • Chloroquine 300mg base weekly (sensitive areas)   │
│     • Mefloquine / Doxycycline (resistant areas)        │
└─────────────────────────────────────────────────────────┘

(d) SPECIAL TYPES OF MALARIA - Control Strategies

Forest malaria: Forest workers at high risk - treated bed nets, repellents, early diagnosis camps
Border malaria: Along international/state borders - intense surveillance, active case detection
Urban malaria (An. stephensi): Breeds in overhead tanks, wells, cisterns - source reduction key
Man-made malaria: Construction projects - anti-larval measures mandated

NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAMME (NVBDCP)

Covers: Malaria, Kala-azar, Filaria, Japanese Encephalitis, Dengue/DHF, Chikungunya
High-risk areas (API ≥ 2): eligible for IRS
India's target: Malaria Elimination by 2030 (National Strategic Plan 2017-2022)

WHO Global Technical Strategy Goals (2016-2030):

Milestone	2020	2025	2030
Reduce mortality vs 2015	≥40%	≥75%	≥90%
Reduce case incidence vs 2015	≥40%	≥75%	≥90%
Malaria-free countries	10	20	35

e) NOTE ON MOSQUIRIX (RTS,S/AS01 Vaccine)

"The long-term hope for progress in these areas now depends on the compliant use of existing and development of new technologies." - Park's PSM

MOSQUIRIX (RTS,S/AS01) is the world's first approved malaria vaccine.

┌──────────────────────────────────────────────────────────────┐
│                    MOSQUIRIX AT A GLANCE                     │
├──────────────────────────────────────────────────────────────┤
│  Full Name    : RTS,S/AS01 (Trade name: Mosquirix)          │
│  Developer    : GlaxoSmithKline (GSK)                        │
│  Type         : Recombinant protein subunit vaccine          │
│  Composition  : Protein fragment from outer surface of       │
│                 P. falciparum, fused with Hepatitis B        │
│                 surface antigen (HBsAg) + AS01 adjuvant     │
│  Target stage : Pre-erythrocytic (Sporozoite stage)          │
│                 (Prevents liver invasion)                    │
│  Dosage       : 4 injections (3 primary + 1 booster)        │
│  Target age   : Children 5-17 months                        │
│  Efficacy     : ~30% reduction in clinical & severe malaria  │
│  Duration     : Protection for NO MORE than 4 years         │
│  Status       : WHO-approved for closely monitored use       │
│  Countries    : Malawi, Ghana, Kenya (pilot programs)        │
│  WHO stance   : Does NOT recommend for infants under 1 year │
└──────────────────────────────────────────────────────────────┘

MECHANISM OF ACTION

Sporozoites injected                   RTS,S antibodies
by mosquito                            generated by vaccine
        │                                      │
        ▼                                      ▼
Sporozoite surface          ──────►    Antibodies BLOCK
(CSP antigen expressed)                sporozoite entry
                                       into LIVER CELLS
                                              │
                                              ▼
                                    Infection PREVENTED
                                    at pre-erythrocytic stage
                                    (before symptoms can develop)

DEVELOPMENT MILESTONES

Year	Event
2012	Phase III clinical trial results published
2015	EMA (European Medicines Agency) positive opinion
2019	WHO pilot program launched in Ghana, Kenya, Malawi
2021	WHO recommended broader use in sub-Saharan Africa
Ongoing	Development of newer adjuvants for improved efficacy

LIMITATIONS OF MOSQUIRIX

Low efficacy (~30%) - insufficient for herd immunity
Short duration - protection wanes after 4 years
4-dose schedule - complex logistics in low-resource settings
Only targets P. falciparum - no protection against P. vivax
Only pre-erythrocytic - does not prevent blood stage disease once established

SIGNIFICANCE

Proof of concept that malaria vaccine is achievable
First vaccine against a parasitic disease to reach widespread use
Part of WHO's multi-pronged strategy alongside ITNs, IRS, and drugs
Further research ongoing - R21/Matrix-M vaccine (Oxford-Serum Institute) showing ~75% efficacy in trials

SUMMARY FLOWCHART: MALARIA CONTROL

┌──────────────────────────────────────────────────────────────┐
│           MALARIA CONTROL STRATEGY (INDIA)                   │
└────────────────────────┬─────────────────────────────────────┘
                         │
        ┌────────────────┼─────────────────┐
        ▼                ▼                 ▼
┌──────────────┐ ┌──────────────┐ ┌──────────────────────┐
│  REDUCE      │ │  REDUCE      │ │  REDUCE              │
│  INFECTION   │ │  MORBIDITY   │ │  TRANSMISSION        │
│  RISK        │ │  & MORTALITY │ │                      │
│              │ │              │ │                      │
│ • ITNs/LLINs │ │ • Early Dx   │ │ • IRS (DDT,          │
│ • Repellents │ │ • RDT/Micro  │ │   Pyrethroids)       │
│ • Screens    │ │ • ACT / CQ + │ │ • Larviciding        │
│ • Chemo-     │ │   Primaquine │ │ • Source reduction   │
│   prophylaxis│ │ • IV Artesu- │ │ • Biological control │
│ • Vaccine    │ │   nate (sev.)│ │ • Surveillance       │
│   (Mosquirix)│ │              │ │ • NVBDCP             │
└──────────────┘ └──────────────┘ └──────────────────────┘

HOW TO PRESENT THIS IN EXAM FOR HIGH SCORE

1. Heading & Introduction (2 marks): Define malaria in 2 lines, mention causative agents.

2. Use numbered headings for each sub-part (a, b, c, d, e) exactly as asked in the question.

3. Draw boxed flow charts / tables wherever you see classification or steps - examiners LOVE visual clarity. Use simple ASCII-style boxes with arrows drawn by hand.

4. Key diagrams to draw:

Transmission chain classification (box diagram)
Life cycle of Plasmodium (two-column human vs mosquito)
Malarial indices classification (pre-eradication vs eradication era)
Mosquirix mechanism (simple arrow diagram)

5. Tables for quick facts: Species vs periodicity table, SPR/SFR formulae - very scoring.

6. Bold key terms and underline definitions.

7. Conclude each section with a 1-line clinical significance or public health implication.

8. In malarial indices section: ALWAYS write the formula for API, ABER, and SPR. Formula writing = guaranteed marks.

9. For Mosquirix: Present as a structured note with development, composition, mechanism, efficacy, limitations - minimum 6 points.

10. End with: "Malaria remains a major public health challenge. A multi-pronged approach combining vector control, early diagnosis, effective treatment, and emerging vaccine strategies is essential for its elimination by 2030."

All content sourced from: Park's Textbook of Preventive and Social Medicine (K. Park) - the standard reference for SPM university examinations. Also referenced: Sherris & Ryan's Medical Microbiology, 8th Edition for Mosquirix data.

This is a shared conversation. Sign in to Orris to start your own chat.